ClinicalTrials.Veeva

Menu

A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue

Medtronic logo

Medtronic

Status

Completed

Conditions

Non-emergent, Soft Tissue Procedures, Performed Via an Open Approach

Treatments

Device: Veriset™ Hemostatic Patch

Study type

Interventional

Funder types

Industry

Identifiers

NCT01719172
COVEUST0278

Details and patient eligibility

About

The objective of this study is to determine the safety of Veriset™ Hemostatic Patch when used during non-emergent, open, soft tissue surgery where a topical hemostatic agent would be used.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject or authorized representative has provided informed consent.
  • Subject is ≥ 18 years old.
  • Subject is scheduled for nonemergent surgery where a topical hemostatic agent would be used to control bleeding emanating from a tissue bed following organ dissection or removal or a bleeding tumor tissue bed following resection or dissection, via an open approach.
  • Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.
  • Subject has an appropriate Target Bleeding Site (TBS) during the surgical procedure.
  • TBS bleeding assessment is Type 2 or 3 (refer to table in protocol).

Exclusion criteria

  • Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding.
  • Subject has an estimated life expectancy of less than 6 months.
  • Subject is scheduled for another planned surgery and the subsequent surgery would jeopardize the previous application of study treatment.
  • Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death.
  • Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with the study.
  • Subject has an active local infection at the TBS.
  • The investigator determines that participation in the study may jeopardize teh safety or welfare of the subject.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

Veriset™ Hemostatic Patch
Experimental group
Description:
Topical hemostat
Treatment:
Device: Veriset™ Hemostatic Patch

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems